ABSTRACT
Whole genome sequencing (WGS) is used to establish genetic relatedness of bacteria and track outbreaks in healthcare settings. While WGS provides sufficient discriminatory power to make inferences about genetic relatedness and transmission for most bacterial species, WGS for Clostridioides difficile often fails to provide discriminatory power, even at low single nucleotide polymorphism (SNP) differences. Multi-locus variable number tandem repeat analysis (MLVA), which analyzes rapidly mutating tandem repeat loci has previously been shown to be useful for this purpose for C. difficile. We investigated whether in silico MLVA can further elucidate genetic relatedness of C. difficile clusters identified by short-read WGS but lacking epidemiological links. Potential healthcare-associated toxin-positive C. difficile isolates were collected at our hospital from November 2016 to November 2019. Short-read WGS was performed on the Illumina platform to cluster isolates with ≤2 SNPs, and Nanopore long-read sequencing was used to resolve MLVA loci within these clustered isolates. Among 666 isolates, 62 unique patient isolates met the ≤2 SNP criterion and underwent MinION sequencing. Of the 105 pairs with 0-2 SNP differences, 79.0% had a summed tandem-repeat difference (STRD) of 0-5, 10.5% had an STRD of 6-10, and 10.5% had an STRD of 11-20. A significant correlation was found between a lower STRD value and the presence of a unit/procedure epidemiological link within low SNP clusters (OR: 0.45; 95% CI: 0.29, 0.70). Our findings demonstrate that MLVA provides additional genomic discrimination for closely related C. difficile isolates identified by WGS, enhancing outbreak investigation precision.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in part by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (R01AI127472). NIH played no role in data collection, analysis, or interpretation; study design; writing of the manuscript; or decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Pittsburgh gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Illumina sequence data are available at NCBI BioProject PRJNA475751.
